Notice: This company has been marked as potentially delisted and may not be actively trading. Proteostasis Therapeutics (PTI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends PTI vs. VSTM, SKYE, IVA, IXHL, NVCT, CKPT, TELO, PBYI, ADAG, and TRAWShould you be buying Proteostasis Therapeutics stock or one of its competitors? The main competitors of Proteostasis Therapeutics include Verastem (VSTM), Skye Bioscience (SKYE), Inventiva (IVA), Incannex Healthcare (IXHL), Nuvectis Pharma (NVCT), Checkpoint Therapeutics (CKPT), Telomir Pharmaceuticals (TELO), Puma Biotechnology (PBYI), Adagene (ADAG), and Traws Pharma (TRAW). These companies are all part of the "medical" sector. Proteostasis Therapeutics vs. Verastem Skye Bioscience Inventiva Incannex Healthcare Nuvectis Pharma Checkpoint Therapeutics Telomir Pharmaceuticals Puma Biotechnology Adagene Traws Pharma Verastem (NASDAQ:VSTM) and Proteostasis Therapeutics (NASDAQ:PTI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends. Does the media favor VSTM or PTI? In the previous week, Verastem's average media sentiment score of 0.38 beat Proteostasis Therapeutics' score of 0.00 indicating that Verastem is being referred to more favorably in the media. Company Overall Sentiment Verastem Neutral Proteostasis Therapeutics Neutral Does the MarketBeat Community believe in VSTM or PTI? Verastem received 290 more outperform votes than Proteostasis Therapeutics when rated by MarketBeat users. Likewise, 65.20% of users gave Verastem an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote. CompanyUnderperformOutperformVerastemOutperform Votes60765.20% Underperform Votes32434.80% Proteostasis TherapeuticsOutperform Votes31759.03% Underperform Votes22040.97% Do insiders and institutionals believe in VSTM or PTI? 88.4% of Verastem shares are owned by institutional investors. Comparatively, 16.6% of Proteostasis Therapeutics shares are owned by institutional investors. 2.2% of Verastem shares are owned by company insiders. Comparatively, 4.8% of Proteostasis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, VSTM or PTI? Verastem has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Proteostasis Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Do analysts rate VSTM or PTI? Verastem currently has a consensus target price of $14.57, indicating a potential upside of 271.72%. Given Verastem's higher possible upside, equities research analysts plainly believe Verastem is more favorable than Proteostasis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Proteostasis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has higher valuation & earnings, VSTM or PTI? Proteostasis Therapeutics has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Proteostasis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$2.60M60.67-$87.37M-$3.34-1.17Proteostasis Therapeutics$5M0.00-$59.13M-$1.16N/A Is VSTM or PTI more profitable? Proteostasis Therapeutics' return on equity of -75.39% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -194.05% -64.48% Proteostasis Therapeutics N/A -75.39%-55.04% SummaryProteostasis Therapeutics beats Verastem on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Proteostasis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTI vs. The Competition Export to ExcelMetricProteostasis TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.57M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.629.47113.8115.12Price / SalesN/A381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / BookN/A5.324.665.02Net Income-$59.13M$153.56M$119.06M$225.46M Proteostasis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIProteostasis TherapeuticsN/AN/AN/AN/A$37.57M$5M-0.6244News CoverageGap UpVSTMVerastem3.4319 of 5 stars$3.61+6.5%$14.57+303.6%-37.9%$145.27M$2.60M-1.0850SKYESkye Bioscience1.6168 of 5 stars$5.15+2.4%$18.67+262.5%+247.5%$144.55MN/A0.0011Gap UpIVAInventiva2.7531 of 5 stars$2.74+1.1%$17.67+544.8%-26.5%$143.79M$15.62M0.00100Gap UpIXHLIncannex Healthcare0.9939 of 5 stars$2.24-0.4%N/A+148.8%$142.20M$12,000.000.003Gap UpNVCTNuvectis Pharma1.8597 of 5 stars$7.57-3.4%$21.00+177.4%-30.3%$141.18MN/A-5.878CKPTCheckpoint Therapeutics3.4135 of 5 stars$3.86+4.9%$12.00+210.9%+90.8%$137.75M$78,000.00-2.0310Short Interest ↑High Trading VolumeTELOTelomir PharmaceuticalsN/A$4.65-5.3%N/AN/A$137.69MN/A0.001Positive NewsPBYIPuma Biotechnology2.4848 of 5 stars$2.76-2.5%$7.00+153.6%+11.3%$135.38M$235.60M14.53185Upcoming EarningsAnalyst UpgradeNews CoverageADAGAdagene3.2775 of 5 stars$3.03+0.3%$5.00+65.0%+127.6%$133.80M$815,746.000.00260Gap UpTRAWTraws Pharma1.7007 of 5 stars$5.06+2.4%N/AN/A$128.05M$226,000.00-0.0417Positive NewsGap Up Related Companies and Tools Related Companies VSTM Alternatives SKYE Alternatives IVA Alternatives IXHL Alternatives NVCT Alternatives CKPT Alternatives TELO Alternatives PBYI Alternatives ADAG Alternatives TRAW Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteostasis Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteostasis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
